- Home
- SKIL vs KYNB Comparison
SKIL vs KYNB Comparison
Compare SKIL & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIL | KYNB |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 32.8M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SKIL | KYNB |
|---|---|---|
| Price | $4.77 | $5.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | ★ 37.7K | 22.9K |
| Earning Date | 09-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.43 | $4.85 |
| 52 Week High | $18.45 | $9.66 |
Technical Indicators
Market Signals| Indicator | SKIL | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 27.05 |
| Support Level | $5.06 | N/A |
| Resistance Level | $8.08 | $7.47 |
| Average True Range (ATR) | 0.41 | 0.39 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 6.21 | 12.96 |
Price Performance
Historical ComparisonAbout SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.